Gastric pentadecapeptide BPC 157 and short bowel syndrome in rats.
The gastric pentadecapeptide BPC 157, which was shown to be safe as an antiulcer peptide in trials for inflammatory bowel disease (PL14736, Pliva), successfully healed intestinal anastomosis and fistula in rat. Therefore, we studied for 4 weeks rats with escalating short bowel syndrome and progressive weight loss after small bowel resection from fourth ileal artery cranially of ileocecal valve to 5 cm beneath pylorus. BPC 157 (10 microg/kg or 10 ng/kg) was given perorally, in drinking water (12 ml/rat/day) or intraperitoneally (once daily, first application 30 min following surgery, last 24 h before sacrifice). Postoperatively, features of increasingly exhausted presentation were: weight loss appearing immediately regardless of villus height, twofold increase in crypt depth and fourfold increase in muscle thickness within the first week, jejunal and ileal overdilation, and disturbed jejunum/ileum relation. In contrast, constant weight gain above preoperative values was observed immediately with BPC 157 therapy, both perorally and parenterally, and villus height, crypt depth, and muscle thickness [inner (circular) muscular layer] also increased, at 7, 14, 21, and 28 days. Moreover, rats treated with pentadecapeptide BPC 157 showed not different jejunal and ileal diameters, constant jejunum-to-ileum ratio, and increased anastomosis breaking strength. In conclusion, pentadecapeptide BPC 157 could be helpful to cure short bowel syndrome.
Sever
Marko
M
Department of Pharmacology, Medical School, University of Zagreb, Salata 11, 10000, Zagreb, Croatia.
Klicek
Robert
R
Radic
Bozo
B
Brcic
Luka
L
Zoricic
Ivan
I
Drmic
Domagoj
D
Ivica
Mihovil
M
Barisic
Ivan
I
Ilic
Spomenko
S
Berkopic
Lidija
L
Blagaic
Alenka Boban
AB
Coric
Marijana
M
Kolenc
Danijela
D
Vrcic
Hrvoje
H
Anic
Tomislav
T
Seiwerth
Sven
S
Sikiric
Predrag
P
D000818:Animals; D000897:Anti-Ulcer Agents / Q000494:pharmacology / Q000627:therapeutic use*; D007421:Intestine, Small / Q000473:pathology; D008297:Male; D010446:Peptide Fragments / Q000494:pharmacology / Q000627:therapeutic use*; D011506:Proteins / Q000494:pharmacology / Q000627:therapeutic use*; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar; D012778:Short Bowel Syndrome / Q000188:drug therapy*
D000897:Anti-Ulcer Agents; D010446:Peptide Fragments; D011506:Proteins; C083833:BPC 157